Will West
No más puestos en curso
Historial de carrera de Will West
Antiguos cargos conocidos de Will West.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Odontis Ltd.
Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Corporate Officer/Principal | 20/11/2009 | 18/01/2011 |
Procter & Gamble Health & Beauty Care | Corporate Officer/Principal | - | - |
Formación de Will West.
London Business School | Masters Business Admin |
Estadísticas
Internacional
Reino Unido | 3 |
Estados Unidos | 2 |
Operativa
Corporate Officer/Principal | 2 |
Masters Business Admin | 1 |
Sectorial
Consumer Services | 2 |
Miscellaneous | 2 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Procter & Gamble Health & Beauty Care | Miscellaneous |
Odontis Ltd.
Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Commercial Services |
- Bolsa de valores
- Insiders
- Will West
- Experiencia